Health AI Register Logo
ProductsPlatformsCompaniesNewsContact
ProductsTRACE4AD

Vendor source

Reviewed 11 May 2026

Completeness Strong (64%)

TRACE4AD provides the subject's level of risk (low or high risk) of having or progressing to Alzheimer's disease dementia within 24 months, by an automatic reading of the subject's brain gray matter obtained from a 3D structural T1-weighted MRI brain study, also in combination with subject's neuropsychological measures.

Supported by 2 papers

TRACE4AD
TRACE4AD
TRACE4AD
TRACE4AD thumbnail 1
TRACE4AD thumbnail 2
TRACE4AD thumbnail 3

Key Features

  • Best neuropsychological predictors
  • Best voxel-based map predictors overlayed on the subject gray matter
  • Cognitive
  • Functional and behavioral deficits of the subject
  • Mild cognitive impairment (MCI) subject risk score (low risk vs high risk) of being affected by or progressing to Alzheimer's disease dementia within 24 months
  • Subject gray matter volume and images with normative comparison

General Information

Product name

TRACE4AD

Modality

MR

Main task

Not specified

Subspeciality

Neuro

Disease targeted

Alzheimer’s disease, dementia

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class I

Verified by Health AI Register

Other certifications

Not specified

Evidence & Research

Technical Specifications

Patient population age

Not specified

Input

T1-weighted, MP-RAGE, 3D MRI; brain, cognitive, functional and behavioral measures

Input format

DICOM, Nifti, Nrrd, Pdf

Output

High vs low risk of being affected by or progressing to AD dementia within 2 years, cognitive functional and behavioral deficits, gray matter volume and images, voxel-based map predictors overlayed on gray matter, best neuropsychological predictors

Output format

PDF

Integration

Stand-alone third party application, Stand-alone webbased

Deployment

Cloud-based, Locally on dedicated hardware

Trigger for analysis

On demand, triggered by a user through e.g. a button click, image upload

Processing time

> 10 minutes

Population

Amnestic Mild Cognitive Impairment (MCI) subjects on the recommendation of neurology specialists

Market Presence

On market since

05-2021

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses, Number of installations, Number of users

Source: Vendor | First published: Apr 19, 2022 | Last updated: May 11, 2026